首页 > 文章详情

Best of SGBCC China 2023早期乳腺癌论坛第二期精彩继续

2023年05月04日

来源：肿瘤资讯

参考文献

1、https://clinicaltrials.gov/ct2/show/NCT02167490.
2、Mayer E L, Dueck A C, Martin M, et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2021,22(2):212-222..
3、Loibl S, Marmé F, Martin M, Untch M, et al. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial. J Clin Oncol. 2021 May 10;39(14):1518-1530.
4、Johnston S, Harbeck N, Hegg R, et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)[J]. J Clin Oncol, 2020,38(34):3987-3998.
5、Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. N Engl J Med. 2021 Jun 24;384(25):2394-2405.
6、Bardia A, Bidard F-C, Neven P, et al. Overall survival results from EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator's choice of endocrine monotherapy for ER+/HER2- advanced breast cancer.2022 SABCS abstract GS3-01.

责任编辑：肿瘤资讯-Hedy
排版编辑：肿瘤资讯-Ivy